Skip to main content
OpenTrials
Completed

NCT Number: NCT05199545

Efficacy Study in Phytotherapy of an Association of Plants in the Improvement of Psychological Well-being

The objective of the study is to compare the effect of a 6-week supplementation with a dietary supplement based on plant extracts to the effect of placebo, in patients with a moderate depressive episode (F32.1 by ICD10 definition) and with moderate symptoms (score HAM-D ≥ 16 and ≤ 23).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CICN - Université Catholique de Louvain

Louvain-la-Neuve, Belgium

About this study

Longitudinal, comparative, randomized, placebo-controlled interventional study in 2 parallel groups, double-blind, monocentre, aimed at demonstrating the superiority of the combination of plants over placebo on depressive symptoms.

Each patient will be followed for a maximum of 6 weeks, with 3 visits to the doctor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 and ≤ 75 years old ;
  • Patient with a moderate depressive episode (F32.1 by ICD10 definition) ;
  • Score HAM-D ≥ 16 and ≤ 23 at inclusion, corresponding to moderate symptoms ;
  • Recent depression (less than 6 months), not managed by antidepressant or psychotherapeutic treatment ;
  • Depressive disorder not requiring, in the opinion of the investigator, initiation of antidepressant drug therapy ;
  • Patient able to understand the study information, read the information leaflet, and willing to sign the consent form ;
  • French speaking patient.

Exclusion criteria

  • Patient with a depressive disorder of another nature or any other mental illness (schizophrenia, bipolarity, alcohol or drug addiction, etc.);
  • Patient at risk of suicide (noted by the investigator, or HAM-D item 3 score > 2) or having attempted suicide in the last 5 years;
  • Depression felt for more than 6 months ;
  • Patient under psychotropic treatment (current or in the month preceding inclusion) (neuroleptic, anxiolytic, hypnotic);
  • Patient on beta-blocker therapy ;
  • Patient on dialysis ;
  • Patient using products containing piperine or St. John's wort, or having a known effect on mood in the last 30 days ;
  • Woman who is pregnant or breastfeeding, or has plans to become pregnant in the next 8 weeks ;
  • Patient with an allergy or contraindication to one of the components of the product under study (rhodiola or saffron) ;
  • Patient unable to understand information related to the study (mental or linguistic disability) ;
  • Patient participating or having participated in the previous 3 months in another clinical trial ;

Treatment and study plan

Dietary Supplement

Dietary Supplement

Dietary supplement under study is based on Rhodiola rosea L. and Crocus sativus L. extracts

Placebo

Other

Placebo of the dietary supplement

Primary outcomes

  1. Evolution of depressive symptoms through Hamilton Depression Scale (HAM-D) at the end of the study

    Time frame: 42 days

    Score HAM-D at D42, adjusted to the value at D0 minimum = 0 and maximum = 53 higher score means a worse outcome

Secondary outcomes

  1. Evolution of depressive symptoms through HAM-D during the study

    Time frame: 42 days

    Evolution of score HAM-D between D0, D21 and D42

  2. Evolution of depressive symptoms through HAM-D sub-scores during the study

    Time frame: 42 days

    Evolution of sub-scores HAM-D between D0, D21 and D42

  3. Rate of responding participants (decrease of ≥ 3 points) at D21

    Time frame: 21 days

    HAM-D score showing a decrease of ≥ 3 points compared to D0

  4. Rate of responding participants (decrease of ≥ 3 points) at D42

    Time frame: 42 days

    HAM-D score showing a decrease of ≥ 3 points compared to D0

  5. Rate of responding participants (decrease of ≥ 5 points) at D21

    Time frame: 21 days

    HAM-D score showing a decrease of ≥ 5 points compared to D0

  6. Rate of responding participants (decrease of ≥ 5 points) at D42

    Time frame: 42 days

    HAM-D score showing a decrease of ≥ 5 points compared to D0

  7. Rate of participants in remission at D21

    Time frame: 21 days

    score HAM-D ≤ 7

  8. Rate of participants in remission at D42

    Time frame: 42 days

    score HAM-D ≤ 7

  9. Evolution of depressive symptoms through Hospital Anxiety and Depression Scale - Depression (HADS-D) during the study

    Time frame: 42 days

    Evolution of sub-scores HADS-D between D0, D21 and D42 minimum = 0 and maximum = 21 higher score means a worse outcome

  10. Evolution of depressive symptoms through Hospital Anxiety and Depression Scale - Anxiety (HADS-A) during the study

    Time frame: 42 days

    Evolution of sub-scores HADS-A between D0, D21 and D42 minimum = 0 and maximum = 21 higher score means a worse outcome

  11. Evolution of physician's general impression of the symptoms during the study

    Time frame: 42 days

    Evolution of Clinical Global Impression-Severity (CGI-S) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome

  12. Evolution of physician's general impression of the symptoms evolution during the study

    Time frame: 42 days

    Evolution of Clinical Global Impression-Improvement (CGI-I) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome

  13. Evolution of patient's general impression of the symptoms evolution during the study

    Time frame: 42 days

    Evolution of Patient Global Impression-Improvement (PGI-I) between D0, D21 and D42 minimum = 1 and maximum = 7 higher score means a worse outcome

  14. Adverse events

    Time frame: 42 days

    Number and type of adverse events

  15. Evolution of patient's functional disability in his or her professional, social and family life during the study

    Time frame: 42 days

    Evolution of Sheehan Disability Score (SDS) between D0, D21 and D42 minimum = 0 and maximum = 44 higher score means a worse outcome

  16. Patient satisfaction with complementation at D21

    Time frame: 21 days

    5-point Likert scale (minimum = 1 and maximum = 5) higher score means a better satisfaction

  17. Patient satisfaction with complementation at D42

    Time frame: 42 days

    5-point Likert scale

  18. Number of intercurrent visits

    Time frame: 42 days

    Number of intercurrent visits

  19. Concomitant drug use

    Time frame: 42 days

    Number and type of concomitant drugs

  20. Compliance at D21

    Time frame: 21 days

    Counting of therapeutic units at D21

  21. Compliance at D42

    Time frame: 42 days

    Counting of therapeutic units at D42

  22. Management prescribed or advised at the end of follow-up

    Time frame: 42 days

    Rate of participants on the same dietary supplement, antidepressant medication, other or without treatment at the end of the study

Sponsors and collaborators

Lead sponsor

Larena SAS

Industry

Collaborators

  • Université Catholique de Louvain

Registry information

Acronym: ROSADE

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jan 20, 2022
Registry last updated
Jul 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.